With a “robust” research and development infrastructure in place, plus several launches and six fresh abbreviated new drug application filings under its belt, ANI Pharmaceuticals, Inc. appeared to be in high spirits as it rounded up its results for the first quarter of 2022.
The company’s net revenues reached $64.5m during the quarter, a year-on-year increase of 16.8% compared to $54.5m in 2021. It...








